The waiting rooms of Kanti Children’s Hospital in Kathmandu
are often a heavy chorus of raspy breaths and high-pitched wheezing. For
parents in Nepal, a child’s sudden struggle to breathe is a terrifying, yet
common, ordeal. While many of these illnesses are dismissed as simple colds, a
new study published in the Journal of Manmohan Memorial Institute of Health
Sciences reveals a more specific culprit hiding in plain sight. Researchers
have spent months peeling back the layers of acute respiratory infections in
the capital city, finding that nearly one in five children seeking care for
respiratory distress is actually fighting the respiratory syncytial virus, or
RSV.
This virus is not a new enemy. It has long been recognized
as a leading cause of lower respiratory tract infections in infants worldwide,
particularly in places where medical resources are stretched thin. Yet, in
Nepal, the specific patterns of how it spreads and whom it strikes most
aggressively have remained somewhat of a mystery until now. Between March and
August 2025, a team led by Ram Krishna Shrestha and Megha Raj Banjara tracked
122 children who arrived at the hospital with symptoms ranging from coughs and
fevers to the alarming whistle of wheezing. They used sophisticated molecular
tools not only to find the virus but to determine which specific version of it
was circulating.
The findings were striking. Out of the 122 children tested,
24 carried the virus. The majority of these cases, roughly 54 percent, were
infants under one year old. There was a noticeable lean toward male children,
who made up two-thirds of the positive cases. Scientists like Shrestha and his
colleagues suggest this male predominance might be linked to biological
factors, such as smaller airway sizes in boys or differences in early immune
responses (Shrestha et al., 2026).
Beyond the raw numbers, the study looked at the "viral
load," or how much of the virus was present in the children’s systems.
Using a measure known as the cycle threshold, they found that the youngest children, those under 12 months, carried significantly more of the virus
than their older peers. This higher viral presence in infants is a major reason
why they often end up sicker, as their immature immune systems and tiny airways
struggle to cope with the heavy viral burden.
One of the more fascinating aspects of the research
involved subtyping the virus into two groups, known as RSV-A and RSV-B. For
years, a quiet debate has simmered in the scientific community about whether
one of these subtypes is more dangerous than the other. Some studies in other
parts of the world have suggested that RSV-A is the more virulent twin, yet the
data from Kathmandu tells a different story. While RSV-A was far more common,
accounting for 75 percent of the infections, the actual symptoms the fever, the
cough, the runny nose were virtually identical across both groups. This
suggests that for a doctor in a clinic, knowing the subtype might not change
how they treat the child sitting in front of them (Shrestha et al., 2026).
However, the study does not claim to have all the answers.
The researchers were careful to note that their work was limited to a single
hospital over a relatively short period. They did not have the means to track
exactly how long children stayed in the hospital or how much extra oxygen they
might have needed. Furthermore, the study focused only on the broad subtypes A
and B, leaving deeper genetic variations unexamined. This leaves a gap in
understanding whether even more specific strains might be responsible for the
most severe cases of pneumonia or bronchiolitis.
What this research changes is the urgency of diagnosis. For
too long, respiratory treatment has been a bit of a guessing game in
high-volume settings. Shrestha and his team argue that integrating molecular
testing like RT-PCR into routine care could revolutionize how these children
are managed. If doctors know exactly what they are fighting, they can make
better decisions, avoid unnecessary antibiotics, and prepare for the seasonal
waves of infection that hit the most vulnerable infants the hardest.
Looking ahead, these findings are a vital piece of the
puzzle for public health policy in Nepal. As the world moves closer to
implementing widespread RSV vaccines, having local data is essential. It tells
health officials exactly who needs the most protection and when they need it.
For the parents in those crowded Kathmandu waiting rooms, this research is a
step toward a future where a child’s raspy breath is met with a fast, accurate
diagnosis and a clear path to recovery.
